Arax Advisory Partners’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.14K | Hold |
1,015
| – | – | ﹤0.01% | 2730 |
|
|
2025
Q1 | $985 | Hold |
1,015
| – | – | ﹤0.01% | 2308 |
|
|
2024
Q4 | $1.19K | Buy |
1,015
+400
| +65% | +$468 | ﹤0.01% | 2134 |
|
|
2024
Q3 | $1.03K | Hold |
615
| – | – | ﹤0.01% | 2242 |
|
|
2024
Q2 | $874 | Buy |
+615
| New | +$874 | ﹤0.01% | 2210 |
|
|
2023
Q3 | – | Sell |
-290
| Closed | -$762 | – | 1328 |
|
|
2023
Q2 | $762 | Buy |
+290
| New | +$762 | ﹤0.01% | 1149 |
|
|
2022
Q3 | – | Sell |
-140
| Closed | -$1K | – | 1224 |
|
|
2022
Q2 | $1K | Buy |
+140
| New | +$1K | ﹤0.01% | 1035 |
|